The VITROS immunodiagnostics products anti-HIV 1+2 assay: A rapid and reliable method for HIV screening

Matthew P. Thompson, Darnely Hidalgo, Anne Kim, M. Qasim Ansari

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background: To ensure increased awareness of HIV status by patients, the Centers for Disease Control and Prevention (CDC) has issued new guidelines that greatly expand screening recommendations. The goal of the present study was to assess the overall reliability, sensitivity, specificity, and turnaround time (TAT) of the VITROS Anti-HIV 1+2 Assay (Ortho Clinical Diagnostics, Rochester, NY) in a large community hospital setting. The assay was recently approved by the Food and Drug Administration (FDA). Methods: We compared our current Abbott HIVAB assay (Abbott Laboratories, Abbott Park, IL) with how the VITROS performed on the random access VITROS ECi/ECiQ System in a head-to-head comparison of 298 patient samples and a retrospective comparison of TAT over an 8-month period of utilization. Results: Our data indicate that the VITROS is as sensitive (100%, n=298) and more specific (98% vs 83%) than the Abbott HIVAB and has a faster average TAT (156 minutes vs 1266 minutes). Conclusions: Use of this rapid and reliable assay will lead to greater awareness of HIV status and, hopefully, a decrease in incidence of HIV disease.

Original languageEnglish (US)
Pages (from-to)209-212
Number of pages4
JournalLaboratory Medicine
Volume42
Issue number4
DOIs
StatePublished - Apr 1 2011

Keywords

  • HIV
  • Rapid testing
  • Screening

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'The VITROS immunodiagnostics products anti-HIV 1+2 assay: A rapid and reliable method for HIV screening'. Together they form a unique fingerprint.

  • Cite this